Pulse Biosciences (NASDAQ: PLSE) stock surged 6.26% in pre-market trading on Friday following the company's fourth-quarter 2024 earnings call, which highlighted significant progress in its nanosecond pulsed field ablation (nsPFA) technology and commercial initiatives.

During the earnings call, CEO Paul Laviolette emphasized the company's advancements in early commercialization of their percutaneous electrode for benign thyroid diseases and progress in clinical feasibility studies for atrial fibrillation treatments. The company also reported strengthening its balance sheet by raising $47.9 million through warrant exercises, ending the year with $118 million in cash and equivalents.

Despite reporting increased GAAP costs and expenses of $20.3 million for Q4 2024, up from $12.5 million in the prior year period, investors appeared to focus on the positive developments. These include the appointment of new leadership, including a new CFO and Chief Medical Officer, and the presentation of encouraging clinical data at various medical conferences. The company's progress in multiple clinical programs and its robust patent portfolio of over 180 issued patents protecting its unique nsPFA technology seem to have boosted investor confidence.

While Pulse Biosciences reported a GAAP net loss of $19.4 million for the quarter, the market's positive reaction suggests that investors are optimistic about the company's long-term potential in the medical device sector, particularly in the areas of thyroid disease treatment and cardiac ablation procedures.